Immunome, Inc. Debt Securities, Available-for-sale, Unrealized Loss
Immunome, Inc. (IMNM) reported Debt Securities, Available-for-sale, Unrealized Loss of $21.00 thousand for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2025-08-06
- Immunome, Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2025-06-30 was $21.00K, a 950.00% increase year-over-year.
- Immunome, Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2025-03-31 was $60.00K, a 233.33% increase year-over-year.
- Immunome, Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2024-06-30 was $2.00K.
- Immunome, Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2024-03-31 was $18.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 3 month | Debt Securities, Available-for-sale, Unrealized Loss 6 month |
|---|---|---|
| 2025-06-30 | $21.00K 10-Q · filed 2025-08-06 | $81.00K 10-Q · filed 2025-08-06 |
| 2025-03-31 | $60.00K 10-Q · filed 2025-05-12 | |
| 2024-06-30 | $2.00K 10-Q · filed 2025-08-06 | $20.00K 10-Q · filed 2025-08-06 |
| 2024-03-31 | $18.00K 10-Q · filed 2025-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |